These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 89175)

  • 21. Passive immunization against Pseudomonas aeruginosa recombinant PilA in a murine burn wound model.
    Mousavi M; Behrouz B; Irajian G; Mahdavi M; Korpi F; Motamedifar M
    Microb Pathog; 2016 Dec; 101():83-88. PubMed ID: 27836762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].
    Minukhin VV; Tsyganenko AIa
    Antibiot Khimioter; 1989 Apr; 34(4):282-6. PubMed ID: 2502083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a glycopolypeptide from the slime of P. aeruginosa on phagocytosis by mouse macrophages.
    Nadaud M
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Jul; 254(4):489-99. PubMed ID: 6426197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
    Daoulas-Le Bourdelles F; Berche P; Véron M
    Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
    Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
    Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
    DiGiandomenico A; Keller AE; Gao C; Rainey GJ; Warrener P; Camara MM; Bonnell J; Fleming R; Bezabeh B; Dimasi N; Sellman BR; Hilliard J; Guenther CM; Datta V; Zhao W; Gao C; Yu XQ; Suzich JA; Stover CK
    Sci Transl Med; 2014 Nov; 6(262):262ra155. PubMed ID: 25391481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phagocytosis and intracellular killing of polymorphonuclear leukocytes against Pseudomonas aeruginosa--effect of vaccination with OEP (original endotoxin protein) on phagocytosis and intracellular killing-- (author's transl)].
    Yamashita N
    Kansenshogaku Zasshi; 1980 Feb; 54(2):84-91. PubMed ID: 6771343
    [No Abstract]   [Full Text] [Related]  

  • 28. Development of immunotherapy for infections due to Pseudomonas aeruginosa.
    Fisher MW
    J Infect Dis; 1974 Nov; 130 Suppl(0):S149-51. PubMed ID: 4138585
    [No Abstract]   [Full Text] [Related]  

  • 29. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains.
    Pier GB; Boyer D; Preston M; Coleman FT; Llosa N; Mueschenborn-Koglin S; Theilacker C; Goldenberg H; Uchin J; Priebe GP; Grout M; Posner M; Cavacini L
    J Immunol; 2004 Nov; 173(9):5671-8. PubMed ID: 15494518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies raised against divalent type b flagellin and pilin provide effective immunotherapy against Pseudomonas aeruginosa infection of mice with burn wounds.
    Saffari M; Behbood S; Irajian G; Khorshidi A; Moniri R; Behrouz B
    Biologicals; 2017 Jan; 45():20-26. PubMed ID: 27836582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection.
    Secher T; Fauconnier L; Szade A; Rutschi O; Fas SC; Ryffel B; Rudolf MP
    J Antimicrob Chemother; 2011 May; 66(5):1100-9. PubMed ID: 21393169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.
    Pollack M
    J Infect Dis; 1983 Jun; 147(6):1090-8. PubMed ID: 6406615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experimental study on the immunotherapy for the Pseudomonas keratitis in rabbits (author's transl)].
    Tanaka N; Ohzeki T; Tanaka I; Kinoshita N
    Nippon Ganka Gakkai Zasshi; 1977 Sep; 81(9):1252-9. PubMed ID: 415535
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients.
    Saravolatz LD; Markowitz N; Collins MS; Bogdanoff D; Pennington JE
    J Infect Dis; 1991 Oct; 164(4):803-6. PubMed ID: 1910070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
    Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
    Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.
    Gomi R; Sharma A; Wu W; Sung B; Worgall S
    Vaccine; 2017 Dec; 35(51):7174-7180. PubMed ID: 29126807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of antipolymorphonuclear leucocyte serum on Pseudomonas aeruginosa infection in rabbits.
    Bullen JJ; Wallis SN; Griffiths E
    Immunology; 1976 May; 30(5):603-10. PubMed ID: 819359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.
    Sawada S; Kawamura T; Masuho Y; Tomibe K
    J Infect Dis; 1985 Nov; 152(5):965-70. PubMed ID: 3930629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. II. Induction of heterologous immunity by mucoid strains of P. aeruginosa.
    Gościniak G; Grzybek-Hryncewicz K
    Arch Immunol Ther Exp (Warsz); 1988; 36(2):185-93. PubMed ID: 3149177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.